Zidovudine_lamivudine has been approved in the United States and in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


zidovudine_lamivudine studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
CNAF3021 / Ecureuil2 IV Long term follow-up of 2 triple combinations CombivirTM + Ziagen™ and Combivir™ + Viracept™ started in HIV-1 infected antiretroviral therapy naïve subjects within 2 years in study CNAF3007-Ecureuil.
NZTA4001 IV A Randomized, Multicenter Study of EPIVIR 150mg BID, RETROVIR 200mg TID and a Protease Inhibitor Versus 3TC 150mg/ZDV 300mg Fixed-Dose Tablet Given BID with a Protease Inhibitor in HIV-1 Infected Subjects
NZTA4003 IV A Pharmacokinetic Evaluation of Methadone Following Co-administration with Combivir in Opiate-dependent Subjects
WE066, EPI40007 IV The Antiretroviral Pregnancy Registry (APR, Registry)
WE490 IV Lactic acid levels in children prenatally and perinatally treated with antiretrovirals to prevent HIV transmission.
CNAF 3010 III Evaluation of efficacy and safety of combination of Combivir TM(AZT/3TC) and abacavir, in HIV-infected patients with an abacavir-susceptible phenotype and who had received Zerit ® (d4T) as first-line treatment with some other antiretrovirals.
NUCB3027 III Phase III trial to compare the efficacy of the combination zidovudine/lamivudine taken either as a single tablet of a fixed-dose combination (zidovudine 300 mg/lamivudine 150 mg) twice daily, or as zidovudine (two 100 mg capsules, three times daily) and lamivudine (one 150 mg tablet, twice daily), in antiretroviral-naïve HIV infected patients.
NZTA4007 III A Phase IIIB, Open-Label, Pilot Study to Evaluate the Efficacy, Tolerability, and Health Care Resource Use in HIV-Infected Incarcerated Subjects Treated Twice Daily for 24 Weeks with COMBIVIR (Lamivudine 150mg/Zidovudine 300mg) plus ZIAGEN (Abacavir) 300mg.
PROF3002 / ATTILA III Open label pilot study to evaluate the effect of antiretroviral drugs on HIV-1 in different compartments (plasma and lymphoid tissues).
NZTA1001 I An Evaluation of the Bioequivalence of a Combined Formulated Tablet Compared to Epivir and Retrovir Administered Concurrently and the Effect of Food on Absorption
ZDVB1003 I A phase I study to evaluate the pharmacokinetics and safety of RETROVIR (zidovudine, ZDV) administered orally in combination with EPIVIR™ (lamivudine, 3TC) to HIV-1 infected pregnant women and their offspring.